XYLOCAINE 0.5% LIQUID

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

LIDOCAINE HYDROCHLORIDE

Saadav alates:

ASTRAZENECA CANADA INC

ATC kood:

N01BB02

INN (Rahvusvaheline Nimetus):

LIDOCAINE

Annus:

5MG

Ravimvorm:

LIQUID

Koostis:

LIDOCAINE HYDROCHLORIDE 5MG

Manustamisviis:

BLOCK/INFILTRATION

Ühikuid pakis:

50 ML

Retsepti tüüp:

Ethical

Terapeutiline ala:

LOCAL ANESTHETICS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0101280003; AHFS:

Volitamisolek:

CANCELLED POST MARKET

Loa andmise kuupäev:

2015-05-31

Toote omadused

COPYRIGHT 1954-2015 ASTRAZENECA CANADA INC.
Page 1 of 31
PRESCRIBING INFORMATION
XYLOCAINE
® PARENTERAL SOLUTIONS
Lidocaine Hydrochloride Injection USP
0.5% lidocaine hydrochloride (5 mg/mL)
1% lidocaine hydrochloride (10 mg/mL)
2% lidocaine hydrochloride (20 mg/mL)
Lidocaine Hydrochloride and Epinephrine Bitartrate Injection USP
1% lidocaine hydrochloride (10 mg/mL) with 1:200,000 epinephrine
(0.005 mg/mL)
1% lidocaine hydrochloride (10 mg/mL) with 1:100,000 epinephrine
(0.010 mg/mL)
2% lidocaine hydrochloride (20 mg/mL) with 1:200,000 epinephrine
(0.005 mg/mL)
Local Anesthetic
AstraZeneca Canada Inc.
1004 Middlegate Road
Mississauga, Ontario
L4Y 1M4
www.astrazeneca.ca
Date of Revision:
February 23, 2015
Submission Control No: 176093
XYLOCAINE
®
is a registered trademark of the AstraZeneca group of companies.
COPYRIGHT 1954-2015 ASTRAZENECA CANADA INC.
Page 2 of 31
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
......................................................................
3
INDICATIONS AND CLINICAL USE
...........................................................................
3
CONTRAINDICATIONS
.................................................................................................
4
WARNINGS AND PRECAUTIONS
...............................................................................
5
ADVERSE REACTIONS
...............................................................................................
12
DRUG INTERACTIONS
...............................................................................................
14
DOSAGE AND ADMINISTRATION
...........................................................................
16
OVERDOSAGE
..............................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
.......................................................... 22
STORAGE AND STABILITY
....................................